Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.
BioVaxys Technology Corp. (OTCQB: BVAXF) is a clinical-stage biopharmaceutical company whose news flow centers on its DPX™ immune-educating platform, oncology vaccine programs, and licensing activities. Company releases describe DPX as a non-systemic antigen delivery technology used to generate targeted and persistent immune responses, with applications in cancer, infectious disease, and antigen desensitization.
Investors following BVAXF news can expect updates on clinical studies of maveropepimut-S (MVP-S) in advanced relapsed-refractory diffuse large B cell lymphoma and platinum-resistant ovarian cancer, as well as early-stage work in non-muscle invasive bladder cancer and HR+/HER2- breast cancer. News items also highlight DPX+SurMAGE, a dual-targeted immunotherapy for bladder cancer, and DPX-based vaccines such as DPX-RSV and DPX+rPA for anthrax.
BioVaxys regularly reports on collaborations and licensing agreements that leverage its lipid-based technologies. Examples include licensing to SpayVac-for-Wildlife, Inc. for single-dose immunocontraceptive vaccines in wildlife and aquaculture, and to Zoetis Inc. for animal health applications. The company also issues updates on research collaborations, such as combining DPX with Sona Nanotech’s Targeted Hyperthermia Therapy™ and exploring DPX as a carrier for mRNA vaccines.
In addition to scientific and clinical developments, BVAXF news covers corporate actions such as amendments to its asset purchase agreement for the DPX portfolio, share consolidation on the Canadian Securities Exchange, and financing-related milestones. For readers tracking BVAXF, this news page aggregates these disclosures so they can monitor progress of the DPX platform, pipeline evolution, and key partnership developments over time.
BioVaxys Technology Corp. announced a non-brokered private placement of up to 9,090,909 units at $0.22 per unit, aiming for total proceeds of approximately $2,000,000. Each unit comprises one common share and a warrant, exercisable for an additional share at $0.50 within 30 months. Proceeds will support research and development and working capital. The closing is pending Canadian Securities Exchange approval and is expected within a week. BioVaxys is focused on developing vaccines and diagnostic technologies for COVID-19 and cancer.
BioVaxys Technology Corp. announced the appointment of Dr. Charles J. Dunton as an Advisor to enhance scientific support for its ovarian cancer vaccine candidate BVX-0918A and the marketing of Papilocare in the U.S. Dr. Dunton, a gynecologist/oncologist with over 30 years of experience, has collaborated with BioVaxys on early clinical trials and is recognized as one of America's Top Doctors for Cancer. The decision aims to advance clinical studies and marketing efforts, reinforcing BioVaxys's strategy in the competitive immuno-oncology market.
BioVaxys Technology Corp. (CSE: BIOV, OTC: BVAXF) announced the appointment of Dr. Adam Coutts as Policy Advisor, effective May 20, 2021. Dr. Coutts, a Senior Research Fellow at the University of Cambridge, specializes in public health policy. CEO James Passin stated that Dr. Coutts' expertise will be crucial in advancing CoviDTH, a novel skin test for T cell immunity to Covid-19, through regulatory and commercial pathways. This low-cost solution aims to aid health systems in vulnerable settings, thereby optimizing vaccine distribution.
BioVaxys Technology Corp. (OTCQB: BVAXF) has announced its uplisting from the OTC Pink Sheets to the OTCQB Venture Market as of May 19, 2021. This mid-tier market is designed for early-stage companies, enhancing the visibility and liquidity of BioVaxys shares. CEO James Passin emphasized that this move will improve access to capital for the company's ongoing development of vaccines for ovarian cancer and COVID-19 diagnostics. BioVaxys currently has two issued patents and plans further clinical trials.
BioVaxys Technology Corp. announced a definitive bioproduction agreement with BioElpida S.A.S. for clinical-grade bioproduction of its ovarian cancer vaccine candidate, BXV-0918A. The agreement focuses on building a GMP facility in Lyon, France, and includes critical technical protocols. BioVaxys plans to submit a regulatory filing for a Phase I study by late 2021, with vaccine supply ready by May 2022. The ovarian cancer market is projected to grow from US$1.2B in 2017 to US$4.6B by 2026, indicating a strong need for innovative treatments in this area.
BioVaxys Technology Corp. (OTC: BVAXF) announced it has filed an intent-to-use trademark application for CoviDTH®, a T-cell immune response diagnostic for SARS-CoV-2. This move aims to secure a distinctive mark as the product approaches the market. Additionally, BioVaxys broadened its intellectual property by filing an international patent application via the Patent Cooperation Treaty for its bihaptenized tumor antigen vaccine platform, covering various cancers, including cervical and ovarian cancer. The company continues to strengthen its vaccine development initiatives.